Researchers at The University of Texas MD Anderson Cancer Center say they've devised a new strategy for attacking breast cancer tumors before they metastasize.
Koning has gained a PMA approval for the first 3-D breast computed tomography scanner to extensively image the breast without compressing it.
Cancer drug researchers have developed some major new drugs for treating HER2-positive breast cancer, but patients still develop resistance to them. Now a team at Dartmouth says it has identified a key pathway for resistance that points to a new class of third-line therapies.
Myriad Genetics is throwing in the towel in its fight to stop other companies from offering diagnostic tests that spot specific genes known to be associated with a higher risk of breast cancer.
About one of every 5 cases of breast cancer are termed triple-negative. They are hard to treat and resistant to some of the therapies currently in use, and as a result patients in this subtype have a worse chance of beating the disease or delaying its progress significantly. But now a team of scientists in the U.K. says that they have identified a gene that appears to drive disease progression and might offer a good target for drug developers.
Pfizer appears to be speeding toward a crucial early FDA approval for palbociclib, a breast cancer treatment with blockbuster potential, pivoting from its failed bid for AstraZeneca and building up an oncology pipeline of its own.
In the troubled cancer vaccine field, where experimental jabs seem to be dropping like flies, a breast cancer vaccine developed at the Washington University School of Medicine in St. Louis has shown promising results in an early clinical trial.
A new study supports the effectiveness of 3-D mammography, which researchers found has the potential to significantly increase the rate of identifying cancer in women with dense breasts who are screened using the digital technology.
Puma Biotechnologies is walking back some bullish prognostications for its breast cancer treatment, delaying its planned FDA submission by as much as a year and lending weight to some creeping doubts about its top prospect.
Puma Biotechnology's closely watched neratinib failed to beat out the blockbuster Herceptin in a mid-stage breast cancer trial, a miss the company said was no surprise as it touted success on a secondary goal.